Mlakar, V., Oehme, I., Oehme, I., Lesne, L., Najafi, S., Najafi, S., . . . Gumy-Pause, F. Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11. Frontiers Media S.A.
Chicago Style (17th ed.) CitationMlakar, Vid, et al. Neuroblastoma Response to RAS-MAPK Inhibitors and APR-246 (eprenetapopt) Co-treatment Is Dependent on SLC7A11. Frontiers Media S.A.
MLA (9th ed.) CitationMlakar, Vid, et al. Neuroblastoma Response to RAS-MAPK Inhibitors and APR-246 (eprenetapopt) Co-treatment Is Dependent on SLC7A11. Frontiers Media S.A.
Warning: These citations may not always be 100% accurate.